摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 7-methyl-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate | 1525623-53-3

中文名称
——
中文别名
——
英文名称
ethyl 7-methyl-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate
英文别名
——
ethyl 7-methyl-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate化学式
CAS
1525623-53-3
化学式
C10H11N3O2
mdl
——
分子量
205.216
InChiKey
RSWSVMYOGCPXIP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    56.5
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE<br/>[FR] OCTAHYDROCYCLOPENTAPYRROLES, LEUR PRÉPARATION ET LEUR UTILISATION
    申请人:UNIV COLUMBIA
    公开号:WO2014152018A1
    公开(公告)日:2014-09-25
    The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatement of diseases characterized by excessive lipofuscin accumulation in the retina.
    本发明提供了具有以下结构的八氢环戊吡咯化合物:(结构表示) 其中psi为不存在或存在,当存在时为键;R1、R2、R3、R4和R5各自独立为H、卤素、CF或C1-C4烷基;R6不存在或存在,当存在时为H、OH或卤素;A不存在或存在,当存在时为C(O)或C(O)NH;B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或(C1-C4烷基)-CO2H,其中当B为CO2H时,A存在且为C(O);且当psi存在时,R6不存在,当psi不存在时,R6存在,或其药用可接受盐,用于治疗以视网膜过度脂褐素积聚为特征的疾病。
  • OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE
    申请人:PETRUKHIN Konstantin
    公开号:US20160024007A1
    公开(公告)日:2016-01-28
    The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.
    本发明提供了八氢环戊吡咯化合物,其结构如下:(结构式表示),其中psi不存在或存在,当存在时为键;R1、R2、R3、R4和R5各自独立地为H、卤素、CF或C1-C4烷基;R6不存在或存在,当存在时为H、OH或卤素;A不存在或存在,当存在时为C(O)或C(O)NH;B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或(C1-C4烷基)-CO2H,其中当B为CO2H时,A存在且为C(O);当psi存在时,R6不存在,当psi不存在时,R6存在,或其药学上可接受的盐,用于治疗以视网膜过多脂褐质沉积为特征的疾病。
  • OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE
    申请人:PETRUKHIN Konstantin
    公开号:US20160046632A1
    公开(公告)日:2016-02-18
    The present invention provides compounds comprising variously substituted octahydropyrrolopyrroles, their synthesis, methods of making, methods of using, compositions and formulations thereof.
    本发明提供了包含各种取代的八氢吡咯吡咯化合物,它们的合成方法,制备方法,使用方法,以及它们的组成和配方。
  • Octahydrocyclopentapyrroles, their preparation and use
    申请人:The Trustees of Columbia University in the City of New York
    公开号:US10421720B2
    公开(公告)日:2019-09-24
    The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.
    本发明提供具有以下结构的八氢环戊吡咯化合物:(结构表示)其中psi不存在或存在,存在时为键;R1、R2、R3、R4和R5各自独立地为H、卤素、CF或C1-C4烷基;R6不存在或存在,存在时为H、OH或卤素;A不存在或存在,存在时为C(O)或C(O)NH;B 是取代或未取代的单环、单车、杂单环、杂单车、苄基、CO2H 或 (C1-C4 烷基)-CO2H,其中当 B 是 CO2H 时,则 A 存在且为 C(O);当 psi 存在时,则 R6 不存在,当 psi 不存在时,则 R6 存在,或其药学上可接受的盐,用于治疗以视网膜中脂褐素过度积累为特征的疾病。
  • Octahydropyrrolopyrroles their preparation and use
    申请人:Petrukhin Konstantin
    公开号:US10787453B2
    公开(公告)日:2020-09-29
    The present invention provides compounds comprising variously substituted octahydropyrrolopyrroles, their synthesis, methods of making, methods of using, compositions and formulations thereof.
    本发明提供了包含各种取代的八氢吡咯吡咯的化合物及其合成、制造方法、使用方法、组合物和制剂。
查看更多

同类化合物

苯甲醇,2-甲基-a-[1-(甲基氨基)环戊基]- 甲基5-氧亚基-4,5-二氢吡唑并[1,5-A]嘧啶-2-甲酸基酯 溴-6-甲基[1,2,4]噻唑并[1,5-a]吡啶 乙基[1,2,4]三唑并[1,5-a]吡啶-2-羧酸酯 三(二甲基氨基)(3H-1,2,3-三唑[4,5-b]吡啶-3-基氧代)膦六氟磷酸盐 [1,2,4]噻唑并[4,3-a]吡啶-7-胺 [1,2,4]噻唑并[4,3-a]吡啶-3-羧酸 [1,2,4]噻唑并[1,5-a]吡啶-8-胺 [1,2,4]噻唑并[1,5-a]吡啶-6-羧酸甲酯 [1,2,4]噻唑并[1,5-a]吡啶-6-羧酸 [1,2,4]噻唑并[1,5-a]吡啶-6-甲腈 [1,2,4]噻唑并[1,5-a]吡啶-6-甲胺 [1,2,4]噻唑并[1,5-a]吡啶-5-羧醛 [1,2,4]噻唑并[1,5-a]吡啶-5-羧酸甲酯 [1,2,4]噻唑并[1,5-a]吡啶-2-羧醛 [1,2,4]三氮唑[1,5-A]吡啶-6-甲醛 [1,2,4]三唑并[4,5-a]吡啶-3-磺酰胺 [1,2,4]三唑并[4,3-a]吡啶-5-羧酸 [1,2,4]三唑并[4,3-a]吡啶-5-硫醇 [1,2,4]三唑并[4,3-A]吡啶-8-胺 [1,2,4]三唑并[4,3-A]吡啶-8-羧酸 [1,2,4]三唑并[4,3-A]吡啶-7-胺 [1,2,4]三唑并[4,3-A]吡啶-7-羧酸 [1,2,4]三唑并[1,5-a]吡啶-7-羧酸 [1,2,4]三唑并[1,5-a]吡啶-6-胺 [1,2,4]三唑并[1,5-a]吡啶-5-羧酸 [1,2,4]三唑并[1,5-a]吡啶 [1,2,4]三唑并[1,5-A]吡啶-7-羧酸甲酯 [1,2,4]三唑并[1,5-A]吡啶-7-硼酸 [1,2,4]三唑[4,3-A]嘧啶-6-羧酸 [1,2,4]三唑[4,3-A]吡啶-3-硫醇 [1,2,4]三唑[1,5-a]吡啶-2-甲酸 [1,2,3]三唑并[1,5-a]吡啶-7-甲醛 [1,2,3]三唑并[1,5-a]吡啶-7-甲酰胺 [1,2,3]三唑并[1,5-a]吡啶-3-甲酰胺 [1,2,3]三唑并[1,5-a]吡啶-3-甲酰氯 N-羟基-7-氮杂苯并三氮唑 N-[5-[(1-甲基乙基)氨基]-7-(三氟甲基)[1,2,4]三唑并[1,5-a]吡啶-2-基]-3-吡啶甲酰胺 N-[5-(环丙基氨基)-7-(三氟甲基)[1,2,4]三唑并[1,5-a]吡啶-2-基]-3-吡啶甲酰胺 N,N-二乙基-7-硝基-1H-1,2,3-三唑并[4,5-c]吡啶-1-乙胺 GLPG-0634 中间体 ALK4/ALK5抑制剂 9-环戊基-7-乙基-3-(2-噻吩基)-6,9-二氢-5H-吡唑并[3,4-c][1,2,4]三唑并[4,3-A]吡啶 8-硝基[1,2,4]三唑并[4,3-a]吡啶 8-硝基[1,2,4]三唑并[1,5-a]吡啶 8-甲氧基-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-甲氧基-5-碘-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-甲基-[1,2,4]三唑并[1,5-A]吡啶 8-甲基-1,2,4噻唑并1,5-a吡啶-2-胺 8-溴2-甲基-[1,2,4]噻唑并[1,5-a]吡啶